BeyondSpring, Inc. - Ordinary Shares (BYSI)
BYSI moved a median of 0.00% 30 minutes after news, and +0.50% by the close. How BYSI actually reacts to news — the realized, point-in-time move the market made, measured across 146 labeled events over the last three years with zero look-ahead.
BYSI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 24% | 123 |
| 30-min | 0.00% | 49% | 138 |
| 60-min | +0.22% | 51% | 142 |
| to close | +0.50% | 51% | 141 |
| Middle 50% of BYSI reactions | -1.01% to +2.67% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 146 |
Half of all BeyondSpring, Inc. - Ordinary Shares news events land between -1.01% and +2.67% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when BYSI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BYSI's baseline. Nothing else.
Recent BYSI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K BeyondSpring Inc. For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.15% | |
| Form 8-K BeyondSpring Inc. For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | -2.04% | -5.22% | |
| Form 8-K BeyondSpring Inc. For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | +3.77% | +8.86% | |
| BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis | Press release | GlobeNewswire | -4.10% | -1.13% | |
| Form 8-K BeyondSpring Inc. For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | -4.10% | -1.13% | |
| Form 8-K BeyondSpring Inc. For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | +1.37% | |
| Form ARS BeyondSpring Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.43% | -1.58% | |
| Form DEF 14A BeyondSpring Inc. For: Oct 13 | SEC filing · Form DEF | SEC EDGAR | -0.43% | -1.58% | |
| Form DEFA14A BeyondSpring Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.43% | -1.58% | |
| BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -3.57% | -15.30% | |
| Form 10-Q BeyondSpring Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.57% | -15.30% | |
| Form 8-K BeyondSpring Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -3.57% | -15.30% | |
| Form 8-K/A BeyondSpring Inc. For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -1.68% | -2.23% | |
| BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value | Press release | GlobeNewswire | — | +6.21% | |
| Form 8-K BeyondSpring Inc. For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | — | +6.21% | |
| BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026 | Press release | GlobeNewswire | -4.65% | -1.16% | |
| BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting | Press release | GlobeNewswire | +10.00% | +7.31% | |
| BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | — | +2.84% | |
| Form 10-Q BeyondSpring Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +3.52% | |
| Form 8-K BeyondSpring Inc. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | — | +2.84% | |
| BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs | Press release | GlobeNewswire | +2.35% | -4.12% | |
| BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026 | Press release | GlobeNewswire | +0.00% | +2.53% | |
| BeyondSpring Files 2025 Annual Report on Form 10-K | Press release | GlobeNewswire | — | -3.59% | |
| BeyondSpring Reports 2025 Year-End Financial Results | Press release | GlobeNewswire | — | +3.70% | |
| Form 10-K BeyondSpring Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | -3.59% | |
| Form 8-K BeyondSpring Inc. For: Mar 25 | SEC filing · Form 8-K | SEC EDGAR | — | +3.70% | |
| BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference | Press release | GlobeNewswire | +0.00% | +0.67% | |
| Form 8-K BeyondSpring Inc. For: Dec 15 | SEC filing · Form 8-K | SEC EDGAR | +4.74% | +4.21% | |
| BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path | Press release | GlobeNewswire | -1.33% | -6.22% | |
| BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 | Press release | GlobeNewswire | +1.99% | +8.46% | |
| Form 8-K BeyondSpring Inc. For: Nov 17 | SEC filing · Form 8-K | SEC EDGAR | — | +0.00% | |
| BeyondSpring Reports Third-Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | +10.42% | |
| Form 10-Q BeyondSpring Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K BeyondSpring Inc. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +10.42% | |
| Form 8-K BeyondSpring Inc. For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | -7.26% | |
| Form 8-K BeyondSpring Inc. For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -1.59% | -5.29% | |
| Form EFFECT BeyondSpring Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | — | |
| BeyondSpring Reports Second-Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment | Press release | GlobeNewswire | +0.00% | -0.50% | |
| Form 10-Q BeyondSpring Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | +0.50% | |
| Form 8-K BeyondSpring Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.50% | |
| Form POS AM BeyondSpring Inc. | SEC filing · Form POS | SEC EDGAR | — | +0.50% | |
| Form DEF 14A BeyondSpring Inc. For: Sep 15 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -4.22% | |
| Form DEFA14A BeyondSpring Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -4.22% | |
| BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure | Press release | GlobeNewswire | +0.00% | -6.20% | |
| Form 8-K BeyondSpring Inc. For: Jul 03 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -6.20% | |
| BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting | Press release | GlobeNewswire | +0.00% | -1.16% | |
| BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting | Press release | GlobeNewswire | -0.29% | -2.35% | |
| BeyondSpring Reports First-Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | +4.25% | |
| Form 10-Q BeyondSpring Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +4.25% | |
| Form 8-K BeyondSpring Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.25% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BYSI section they belong to.
Where else BYSI is measured.
BYSI earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| INMED PHARMACEUTICALS (IMLFF) | 148 | 0.00% | 48% |
| Akari Therapeutics Plc - American Depositary Shares (AKTX) | 146 | 0.00% | 45% |
| Clearside Biomedical, Inc. (CLSD) | 145 | 0.00% | 46% |
| Oramed Pharmaceuticals Inc. (ORMP) | 145 | +0.69% | 69% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BeyondSpring, Inc. - Ordinary Shares's median reaction calculated?
Every labeled BYSI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 146 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of BYSI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BYSI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.